Acute Bacterial Exacerbation of Chronic Bronchitis
Adults and Children (12 yr of age and older): PO 400 mg twice daily for 10 days.
Pharyngitis/Tonsillitis and Uncomplicated Skin and Skin Structure Infections
Adults and Children (12 yr of age and older): PO 200 mg twice daily for 10 days.
Renal Function Impairment
Adults and Children (12 yr of age and older):
Mild renal impairment (Ccr 50 to 80 mL/min/1.73 m2 ): PO No dosage adjustment is necessary.
Moderate renal impairment (Ccr 30 to 49 mL/min/1.73 m2 ): PO less than 200 mg twice daily.
Severe renal impairment (Ccr less than 30 mL/min/1.73 m2 ): PO 200 mg daily.
End-stage renal disease: PO Dose not determined.
Administer each dose with food to increase absorption.
Inhibits mucopeptide synthesis in bacterial cell wall.
Hypersensitivity to cephalosporins or milk protein; carnitine deficiency or inborn errors of metabolism that result in clinically important carnitine deficiency.
Use Cautiously in:
CNS: Headache; reversible hyperactivity; seizures.
DERM: Stevens-Johnson syndrome; erythema multiforme; toxic epidermal necrolysis.
GI: Diarrhea; nausea; abdominal pain; dyspepsia; vomiting; pseudomembranous colitis; colitis.
GU: Vaginal moniliasis; hematuria; increased urine WBC; renal dysfunction; toxic nephropathy.
HEMA: Decreased hematocrit; aplastic anemia; hemolytic anemia; hemorrhage; pancytopenia; neutropenia; agranulocytosis.
HEPA: Hepatic dysfunction (eg, cholestasis).
METAB: Increased glucose.
OTHER: Allergic reactions; anaphylaxis; drug fever; hypertonia; superinfection; serum sickness-like reaction.
Antacids, H2 -receptor antagonists (eg, famotidine)
May decrease cefditoren plasma levels, possibly reducing the efficacy.
May increase plasma levels and the duration of activity of cefditoren.
Therapeutic Classification: anti-infectives
Pharmacologic Classification: third generation cephalosporins
Absorption: Cefditoren pivoxil is a prodrug that is converted to cefditoren (the active component) in GI tract during absorption. Bioavailability 14% in fasting state, increased by high fat meal.
Distribution: Widely distributed.
Protein Binding: 88%.
Metabolism/Excretion: Mostly excreted unchanged by the kidneys.
Half-life: 1.6 hr (increased in renal impairment).
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal